300558.SZ · 贝达药业
China A-shares · RS rating 25 · As of 2026-10-14
| Price | 43.22 CNY |
|---|---|
| 1-day change | -4.1% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 29 / 10 / 19 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 26 / 19 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -10.0% |
| Distance from 52-week high | +40.7% |
| Market cap (USD) | $3.1B |